In previous studies, the proportion of oligoprogression was reported to be 15–47% in patients with NSCLC with driver oncogenes and who showed AR to targeted therapy [13, 17, 18], which is lower than that reported in our study. The gene discussed is AR; the disease is non-small cell lung carcinoma.